KLISYRI® (tirbanibulin) is Now FDA Approved. Learn more

Recent News

Athenex to Provide a Corporate and Financial Update for the Fourth Quarter and Full Year 2020 on March 1, 2021

Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin

Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy and Safety of Klisyri® (tirbanibulin)

CEO Dr. Johnson Lau Recuperating from COVID at Home

CEO Dr. Johnson Lau Contracts COVID-19

Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference

Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

Athenex Presents Updated Phase 3 Data on Survival and Tolerability Associated with Oral Paclitaxel and Encequidar in Patients with Metastatic Breast Cancer

Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosphamide

Our Science

We are focused on discovering and developing novel therapies for treating cancer and addressing unmet medical needs.
Learn more

Investors

View press releases, events and presentations, and other investment information.
Learn more

Join Our Team

As the Company grows, we are always looking to add talented professionals to join the Athenex family.
Learn more

Other Highlights

Photography by Christopher Galluzzo / Nasdaq, Inc.

Photography by Christopher Galluzzo / Nasdaq, Inc.

On June 14, 2017, Athenex celebrated its initial public offering (IPO) at the Nasdaq MarketSite in Times Square.
Athenex is building a 409,000 square foot manufacturing facility in Dunkirk, NY, with support from New York State.